Single Orbital Metastasis in Castration-Resistant Prostate Cancer
Authors
Abstract:
Introduction: Orbital metastasis of prostate cancer (PC) is very rare and even more unique in castration-resistant PC (CRPC). In this scenario, choline positron emission tomography/computed tomography (choline PET/CT) is the gold-standard restaging method of choice available in our setting, and new anti-androgens treatments show improvement in overall survival. Case presentation: We report the case of a 69-year-old male patient diagnosed with PC, treated with radical prostatectomy, and salvage radiotherapy after biochemical recurrence. After new prostate-specific antigen (PSA) progression, androgen deprivation therapy (ADT) was started. Four and a half years later, and already labeled as non-metastatic CRPC with a negative extension study, including choline PET/CT, he developed an accidental left frontal head trauma, presenting with proptosis, palpebral oedema, and oculomotor disorder. Computed tomography (CT) and magnetic resonance imaging (MRI) showed a destructive bone lesion in the left orbit, associated with a soft tissue mass. These findings, suggestive of a neoplastic lesion, were histologically confirmed PC metastasis. Treatment was initiated with abiraterone, with a rapid improvement of symptoms, a progressive decrease of PSA, and a significant radiological response. Conclusion: Orbital metastases may present with proptosis and should be considered in patients with a history of cancer. If the ocular-orbital disease is suspected, the nuclear medicine physician should be aware that the choline PET/CT imaging includes the orbits. Tolerability and response to treatment with abiraterone were excellent.
similar resources
Castration-resistant Prostate CanCer
• Objective: To review therapeutics for castrationresistant prostate cancer (CRPC). • Methods: Literature review. • Results: Targeting of androgen-dependent pathways in CRPC post-chemotherapy has been shown to improve survival with the lyase inhibitor abiraterone and lead to PSA and objective responses with an androgen receptor antagonist (MDV3100). However, the addition of bevacizumab to docet...
full textNonmetastatic Castration-Resistant Prostate Cancer
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation. When these local treatments fail by the definition of increasing PSA levels, patients are usually treated with an...
full textComplete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
full text
Orbital metastasis from prostate cancer.
To cite: Ahmed M, Begum T. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2015211447 DESCRIPTION An 82-year-old man presented with proptosis, progressive throbbing pain and blurry vision in the right eye, gradually worsening over the past 3 weeks. The patient was diagnosed with prostate cancer and had undergone a radical prostatectomy nearly 14 years prior. After...
full textAbout sorafenib in castration-resistant prostate cancer.
In the study design of Chi et al. [1] is declared that sorafenib would be considered of interest if three or more prostatespecific antigen (PSA) responses were observed in the 25 patients accrued. In their trial, a PSA response occurred in one patient among 28 patients treated with sorafenib; therefore, sorafenib should be considered ineffective in chemonaive castration-resistant prostate cance...
full textMy Resources
Journal title
volume 4 issue 4
pages 1- 4
publication date 2020-10
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023